Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
Asahi Kasei has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
There will be no immediate impact on the company’s supply of derivative products. The businesses covered by this initiative recorded revenue of ¥116.2 billion in fiscal year 2025, compared with ¥1,306.2 billion for the Material segment overall.
| Product | Applications | FY 2030 Scope |
| Styrene monomer | Resin feedstock, etc. | Discontinuation of production |
| Suntec™-LD and Suntec™-EVA low-density polyethylene (LDPE) |
Various films, packag-ing materials, sundry goods, etc. | |
| Suntec™-HD and Creolex™ high-density polyethylene (HDPE) |
||
| Acrylonitrile (AN) | Resin feedstock, fiber feedstock, etc. | Discontinuation of Mizushima 200 kt/y AN line and conversion of 50 kt/y MAN (meth-acrylonitrile) line to AN/MAN co-produc-tion, with continued AN supply through Tongsuh Petrochemical (South Korea). |
| Duranol™ polycarbonate diol (PCD) | Polyurethane feed-stock for synthetic leather, etc. |
Discontinuation of Mizushima ≈3 kt/y PCD line; supply maintained via Asahi Kasei Per-formance Chemicals (China), etc. |
Asahi Kasei’s discontinuation of these derivatives and realignment of its supply chain form part of a broader initiative to streamline its Material sector portfolio and enhance capital efficiency.
These measures are intended to exit businesses where profitability has become inherently challenging and to restructure the related supply chains within the global petrochemical markets. This is expected to improve margins and reduce cash outflows associated with maintaining these operations, enabling the strategic reallocation of capital toward higher-value opportunities. Such disciplined portfolio man-agement reinforces Asahi Kasei’s focus on areas with stronger long-term return potential.
Under its three-year medium-term management plan "Trailblaze Together," Asahi Kasei is improving capital efficiency and accelerating earnings by converting past growth investments into tangible returns. To support this, the company is implementing structural reforms that channel resources to its key growth pillars—pharmaceuticals, critical care, overseas homes, and electronics.
Recent actions such as entering a basic agreement with Mitsui Chemicals and Mitsubishi Chemical to promote the decarbonization of ethylene production in western Japan, and acquiring Aicuris to strengthen its specialty pharma platform in severe infectious diseases, demonstrate Asahi Kasei’s dis-ciplined execution of this strategy and reinforce the foundation for sustained, profitable growth.
Asahi Kasei